Mobile

Refametinib given to patients with unresectable or metastatic HCC carrying a RAS mutation

Update Il y a 4 ans
Reference: EUCTR2013-000311-25

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective is to evaluate the efficacy of refametinib in patients with KRAS or NRAS mutant unresectable or metastatic HCC.

Inclusion criteria

  • KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)

Links